| Diana L Kane, MD | |
|
701 E Marshall St, West Chester, PA 19380-4412 | |
| (610) 431-5150 | |
| Not Available |
| Full Name | Diana L Kane |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 701 E Marshall St, West Chester, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679580955 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD070213L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Care Specialists Pc | 4082517479 | 14 |
News Archive
New research from the University of Sydney finds that even low levels of alcohol consumption during pregnancy can have an impact on a child's brain development and is associated with greater psychological and behavioral problems in youth including anxiety, depression and poor attention.
In follow-up coverage of the WHO's announcement Wednesday of a plan to contain the spread of artemisinin-resistant malaria, news outlets examined the scope of the problem, reactions to the plan and speculations of how the anticipated $175 million annual cost would be funded.
The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.
The quest for genetic information in the fight against prostate cancer is nearly two decades long. While researchers and doctors have long accepted the hereditary nature of the disease, in that closer relatives are at a two-fold increased risk of developing prostate cancer, the genetic explanation remained a mystery. Last week geneticists shared news of a novel gene mutation linked to familial prostate cancer risk.
GE is helping to transform the delivery of patient care with Venue™ 40, a miniaturized ultrasound system with advanced touch-screen technology, launched by GE Healthcare, a business unit of General Electric Company. Venue 40 is portable, allowing physicians to quickly perform rapid diagnostics and needle-guided procedures right at a patient's bedside, providing real-time results.
› Verified 2 days ago
| Entity Name | Emergency Care Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023044278 PECOS PAC ID: 4082517479 Enrollment ID: O20040202000309 |
News Archive
New research from the University of Sydney finds that even low levels of alcohol consumption during pregnancy can have an impact on a child's brain development and is associated with greater psychological and behavioral problems in youth including anxiety, depression and poor attention.
In follow-up coverage of the WHO's announcement Wednesday of a plan to contain the spread of artemisinin-resistant malaria, news outlets examined the scope of the problem, reactions to the plan and speculations of how the anticipated $175 million annual cost would be funded.
The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.
The quest for genetic information in the fight against prostate cancer is nearly two decades long. While researchers and doctors have long accepted the hereditary nature of the disease, in that closer relatives are at a two-fold increased risk of developing prostate cancer, the genetic explanation remained a mystery. Last week geneticists shared news of a novel gene mutation linked to familial prostate cancer risk.
GE is helping to transform the delivery of patient care with Venue™ 40, a miniaturized ultrasound system with advanced touch-screen technology, launched by GE Healthcare, a business unit of General Electric Company. Venue 40 is portable, allowing physicians to quickly perform rapid diagnostics and needle-guided procedures right at a patient's bedside, providing real-time results.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Diana L Kane, MD Po Box 425, Lederach, PA 19450-0425 Ph: (800) 528-0006 | Diana L Kane, MD 701 E Marshall St, West Chester, PA 19380-4412 Ph: (610) 431-5150 |
News Archive
New research from the University of Sydney finds that even low levels of alcohol consumption during pregnancy can have an impact on a child's brain development and is associated with greater psychological and behavioral problems in youth including anxiety, depression and poor attention.
In follow-up coverage of the WHO's announcement Wednesday of a plan to contain the spread of artemisinin-resistant malaria, news outlets examined the scope of the problem, reactions to the plan and speculations of how the anticipated $175 million annual cost would be funded.
The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.
The quest for genetic information in the fight against prostate cancer is nearly two decades long. While researchers and doctors have long accepted the hereditary nature of the disease, in that closer relatives are at a two-fold increased risk of developing prostate cancer, the genetic explanation remained a mystery. Last week geneticists shared news of a novel gene mutation linked to familial prostate cancer risk.
GE is helping to transform the delivery of patient care with Venue™ 40, a miniaturized ultrasound system with advanced touch-screen technology, launched by GE Healthcare, a business unit of General Electric Company. Venue 40 is portable, allowing physicians to quickly perform rapid diagnostics and needle-guided procedures right at a patient's bedside, providing real-time results.
› Verified 2 days ago
Francis Xavier Speidel, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 215 William Penn Blvd, West Chester, PA 19382 Phone: 610-399-1476 | |
Christopher J Ware, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5150 | |
Franklin Kelton, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 701 East Marshal Street, West Chester, PA 19381 Phone: 888-996-4334 Fax: 856-616-1919 | |
Matthew Mcmullan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5550 | |
Dr. John A Contino, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1572 Wilmington Pike, Suite 1, West Chester, PA 19382 Phone: 610-459-3278 Fax: 610-459-8642 | |
Ricardo Gelman, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5150 | |
Richard B Stiles, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 701 East Marshal Street, West Chester, PA 19381 Phone: 610-431-5150 |